Antares Pharma Revenue and Competitors

Ewing, NJ USA

Location

$45M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Antares Pharma's estimated annual revenue is currently $63.6M per year.(i)
  • Antares Pharma received $46.0M in venture funding in May 2015.
  • Antares Pharma's estimated revenue per employee is $683,376
  • Antares Pharma's total funding is $45M.

Employee Data

  • Antares Pharma has 93 Employees.(i)
  • Antares Pharma grew their employee count by -22% last year.

Antares Pharma's People

NameTitleEmail/Phone
1
SVP, OperationsReveal Email/Phone
2
EVP, General Counsel, Human Resources, Chief Compliance Officer and Corporate SecretaryReveal Email/Phone
3
SVP, Device Business and AlliancesReveal Email/Phone
4
VP, Pharmaceutical DevelopmentReveal Email/Phone
5
SVP, Head CommercialReveal Email/Phone
6
SVP, Regulatory Affairs And Quality AssuranceReveal Email/Phone
7
Director Manufacturing EngineeringReveal Email/Phone
8
Director / Head ITReveal Email/Phone
9
Director, National AccountsReveal Email/Phone
10
Materials ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M25-11%N/AN/A
#2
$35.8M1788%N/AN/A
#3
$5.4M27-25%N/AN/A
#4
$4180M145161%$550MN/A
#5
$12.5M6215%N/AN/A
#6
$6.7M119-37%$199.6MN/A
#7
$9.4M477%N/AN/A
#8
$10.3M516%N/AN/A
#9
$106.3M52916%N/AN/A
#10
$15.5M7720%N/AN/A
Add Company

What Is Antares Pharma?

Antares Pharma, Inc., develops and commercializes parenteral therapeutic products using advanced drug delivery systems for improved safety and efficacy, reduced side effects, and enhanced patient comfort and adherence. We apply our drug delivery systems in collaborations with pharmaceutical partners to enhance our partners' drug compounds. We believe that we offer a distinct value to patients, physicians, pharmaceutical partners and our shareholders. Our products typically improve safety and efficacy profiles by minimizing dosing and reducing side effects while improving patient compliance. We focus on self-injection pharmaceutical products and technologies and topical gel -based products. Our subcutaneous injection technology platforms include Vibex disposable pressure-assisted auto injectors, Vision® reusable needle-free injectors, and disposable multi-use pen injectors.

keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals

$45M

Total Funding

93

Number of Employees

$63.6M

Revenue (est)

-22%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Antares Pharma News

2022-04-13 - Halozyme signs agreement to acquire Antares Pharma for ...

The acquisition will result in the creation of a drug delivery and speciality product company. ... Antares focuses on developing pharmaceutical...

2022-04-13 - Antares Pharma to be acquired by Halozyme in $960M deal ...

Antares, which was originally founded in Exton, is a specialty pharmaceutical company that develops, manufactures and commercializes therapeutic...

2022-04-13 - Halozyme Therapeutics Agrees to Buy Antares Pharma

Halozyme Therapeutics Inc. HALO 0.60% agreed to a nearly $1 billion deal to buy specialty pharmaceutical company Antares Pharma Inc. ATRS...

2021-07-22 - Antares Pharma : Announces FDA Acceptance of IND Application for ATRS 1902 For Adrenal Crisis Rescue

ANTARES PHARMA ANNOUNCES FDA ACCEPTANCE OF IND APPLICATION FOR ATRS-1902 FOR ADRENAL CRISIS RESCUE EWING, NJ, July 22, 2021 - Antares Pharma, Inc. (NASDAQ: ATRS) ("the Company"), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted th ...

2019-09-08 - BNP Paribas Arbitrage SA Reduces Holdings in Antares Pharma Inc (NASDAQ:ATRS)

BNP Paribas Arbitrage SA trimmed its holdings in shares of Antares Pharma Inc (NASDAQ:ATRS) by 43.1% in the second quarter, according to ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$35M1240%N/A
#2
$18.6M128-7%N/A
#3
$7.5M14460%N/A
#4
$548.8M2047%$20.3M
#5
$15M3451%N/A

Antares Pharma Funding

DateAmountRoundLead InvestorsReference
2002-07-16$2.0MPrivate PlacementArticle
2003-07-23$4.0MPrivate PlacementArticle
2005-10-20$2.0MUndisclosedArticle
2006-03-07$11.0MUndisclosedSCO Securities LLC, Dawson James Securities IncArticle
2007-03-01$10.0MUndisclosedMMV Financial Inc, HSBC Capital (Canada) IncArticle
2007-03-27$1.8MUndisclosedBradley Pharmaceuticals IncArticle
2007-07-02$15.0MUndisclosedOppenheimer and Co. IncArticle
2007-07-11$16.0MUndisclosedArticle
2009-07-27$8.5MUndisclosedCowen Group IncArticle
2009-07-31$UndisclosedUndisclosedCowen and Company LLCArticle
2011-05-19$21.4MUndisclosedOppenheimer & Co IncArticle
2012-10-04$47.0MUndisclosedJefferies & Company Inc, Oppenheimer and Co IncArticle
2015-05-07$46.0MUndisclosedPiper Jaffray & CoArticle